CARsgen Therapeutics Holdings Limited (2171.HK) Income Statement 2019 — 2022

Select a metric from the list below to chart it

Dec '19

Dec '20

Dec '21

Dec '22

Income Statement	Dec '19	Dec '20	Dec '21	Dec '22
Revenue	—	—	3.8	—
Gross Profit	—	—	3.8	—
Gross Profit Margin	—	—	100.0%	—
R&D Expenses	30.6	41.0	73.1	99.1
Selling, General, & Admin Expenses	1.3	8.0	9.6	6.8
Other Expenses	1.7	1.8	6.4	10.9
Operating Income	-33.1	-47.6	-85.4	-128.4
Operating Income Margin	—	—	-2270.1%	—
Total Other Income/Expenses Net	-5.5	-107.3	-604.6	-1.4
Income Before Tax	-38.6	-155.0	-689.9	-129.8
Income Before Tax Margin	—	—	-18350.4%	—
Income Tax Expense	5.6	105.5	1.1	0.2
Net Income	-44.2	-260.5	-691.0	-130.0
Net Income Margin	—	—	-18380.0%	—
Weighted Avg. Shares Out	567.3	567.3	386.8	—
EPS	-0.1	-0.5	-1.8	—
EPS % Chg.	—	494.3%	289.2%	—
Weighted Avg. Shares Out Dil	567.3	567.3	386.8	—
EPS Diluted	-0.1	-0.5	-1.8	—
Interest Income	0.4	0.1	1.4	4.0
Interest Expense	0.1	2.0	1.6	2.3
EBIT	-38.3	-156.8	-690.1	-128.0
EBIT Margin	—	—	-18355.2%	—
Depreciation & Amortization	3.1	6.0	9.9	12.7
EBITDA	-35.3	-150.9	-680.2	-115.3
EBITDA Margin	—	—	-18091.4%	—

CARsgen Therapeutics Holdings Limited (2171.HK)